{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T09:43:59Z","timestamp":1792489439922,"version":"4.5.0"},"reference-count":33,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japan Society for the Promotion of Science","award":["18K08806"],"award-info":[{"award-number":["18K08806"]}]},{"name":"Japan Society for the Promotion of Science","award":["19K09293"],"award-info":[{"award-number":["19K09293"]}]},{"name":"Japan Society for the Promotion of Science","award":["19K16786"],"award-info":[{"award-number":["19K16786"]}]},{"name":"Japan Society for the Promotion of Science","award":["20K97688"],"award-info":[{"award-number":["20K97688"]}]},{"award":["18K08806"],"award-info":[{"award-number":["18K08806"]}],"id":[{"id":"https:\/\/ror.org\/00hhkn466","id-type":"ROR","asserted-by":"publisher"}]},{"award":["19K09293"],"award-info":[{"award-number":["19K09293"]}],"id":[{"id":"https:\/\/ror.org\/00hhkn466","id-type":"ROR","asserted-by":"publisher"}]},{"award":["19K16786"],"award-info":[{"award-number":["19K16786"]}],"id":[{"id":"https:\/\/ror.org\/00hhkn466","id-type":"ROR","asserted-by":"publisher"}]},{"award":["20K97688"],"award-info":[{"award-number":["20K97688"]}],"id":[{"id":"https:\/\/ror.org\/00hhkn466","id-type":"ROR","asserted-by":"publisher"}]},{"name":"University of Occupational and Environmental Health","award":["UOEH-R3"],"award-info":[{"award-number":["UOEH-R3"]}]},{"award":["UOEH-R3"],"award-info":[{"award-number":["UOEH-R3"]}],"id":[{"id":"https:\/\/ror.org\/0590fg074","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Published data on reliable prognostic biomarkers for pulmonary pleomorphic carcinoma (PPC), a rare, aggressive subtype of non-small cell lung cancer, are limited. Programmed death-ligand 1 (PD-L1) has been studied; however, the prognostic impact of other immunoregulatory molecules, such as CD73, CD155, and Ki-67 and their combined expression profiles, remains unclear. Methods: We retrospectively analyzed data of 47 patients who had undergone macroscopic complete resection of PPC between January 2000 and December 2022. Immunohistochemistry for PD-L1, CD73, CD155, and Ki-67 was performed. Cut-off values were determined by receiver operating characteristic analysis for cancer-specific death. The primary endpoint was the association between each biomarker and overall survival (OS) or cancer-specific survival (CSS). The secondary endpoint was the prognostic value of combined biomarker profiles, particularly PD-L1 with CD73, CD155, or Ki-67. Results: At a positivity threshold of 1%, the positivity rates were 70.2% for PD-L1, 89.4% for CD73, 91.5% for CD155, and 83.0% for Ki-67. There were no statistically significant differences in OS or CSS between groups with high expression and those with low expression for any single marker. Secondary endpoint analysis showed that low PD-L1 and low CD73 predicted significantly poorer OS (p = 0.046) and low PD-L1 and low Ki-67 predicted significantly poorer CSS (p = 0.039) compared with other combinations. Conclusions: Primary endpoint analyses showed no statistically significant association between any single marker and prognosis in PPC. In contrast, secondary endpoint findings indicated that concurrent low PD-L1 with either low CD73 or low Ki-67 identified subsets with significantly poorer outcomes. The present findings provide a basis for further investigation of biomarker combinations for prognostic assessment in this rare lung cancer. Because of the limited sample size, these findings are exploratory and require validation in larger independent cohorts.<\/jats:p>","DOI":"10.3390\/cancers18142240","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:53:58Z","timestamp":1783932838000},"page":"2240","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stratification of Prognosis in Pulmonary Pleomorphic Carcinoma Based on Integrated PD-L1 and Multiparametric Biomarker Analysis"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1184-4044","authenticated-orcid":false,"given":"Yohei","family":"Honda","sequence":"first","affiliation":[{"name":"Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Shimajiri","sequence":"additional","affiliation":[{"name":"Second Department of Pathology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7444-6158","authenticated-orcid":false,"given":"Takehiko","family":"Manabe","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Nemoto","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rintaro","family":"Oyama","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumasa","family":"Nishizawa","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Matsumiya","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1457-2656","authenticated-orcid":false,"given":"Yusuke","family":"Nabe","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4436-2850","authenticated-orcid":false,"given":"Masaru","family":"Takenaka","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Uramoto","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1758835920950207","DOI":"10.1177\/1758835920950207","article-title":"Pulmonary sarcomatoid carcinoma: Progress, treatment and expectations","volume":"12","author":"Li","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification","volume":"10","author":"Travis","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00000478-200303000-00004","article-title":"Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: A clinicopathologic and immunohistochemical study of 75 cases","volume":"27","author":"Rossi","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1097\/PAS.0b013e3181804302","article-title":"Pleomorphic carcinoma of the lung: Clinicopathologic characteristics of 70 cases","volume":"32","author":"Mochizuki","year":"2008","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1002\/ijc.24610","article-title":"EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: Implications for anti-EGFR treatment of a rare lung malignancy","volume":"125","author":"Italiano","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.cllc.2011.11.004","article-title":"The value of biomarkers in patients with sarcomatoid carcinoma of the lung: Molecular analysis of 33 cases","volume":"13","author":"Jiang","year":"2012","journal-title":"Clin. Lung Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/jso.25041","article-title":"Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung","volume":"117","author":"Imanishi","year":"2018","journal-title":"J. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8738","DOI":"10.18632\/oncotarget.14434","article-title":"Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer","volume":"8","author":"Inoue","year":"2017","journal-title":"Oncotarget"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1080\/14796694.2024.2354160","article-title":"PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer","volume":"20","author":"Barlesi","year":"2024","journal-title":"Future Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Yeo, J., Ko, M., Lee, D.H., Park, Y., and Jin, H.S. (2021). TIGIT\/CD226 axis regulates anti-tumor immunity. Pharmaceuticals, 14.","DOI":"10.3390\/ph14030200"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40364-023-00543-z","article-title":"Targeting TIGIT for cancer immunotherapy: Recent advances and future directions","volume":"12","author":"Zhang","year":"2024","journal-title":"Biomark. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): Primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/j.jtho.2021.07.027","article-title":"Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1\/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC","volume":"16","author":"Shirasawa","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"aar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamaoncol.2019.1549","article-title":"Comparison of biomarker modalities for predicting response to PD-1\/PD-L1 checkpoint blockade: A systematic review and meta-analysis","volume":"5","author":"Lu","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"ref_22","first-page":"100532","article-title":"Predictive value of combined positive score and tumor proportion score for immunotherapy response in advanced NSCLC","volume":"4","author":"Ulas","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrclinonc.2017.88","article-title":"Monitoring immune-checkpoint blockade: Response evaluation and biomarker development","volume":"14","author":"Nishino","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_25","unstructured":"(2024, June 30). Cell Signaling Technology\u00ae. Available online: https:\/\/www.cellsignal.jp\/."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"17588359241249041","DOI":"10.1177\/17588359241249041","article-title":"Role of immunotherapy in pulmonary sarcomatoid carcinoma: Review of current approaches and related biomarkers","volume":"16","author":"Ding","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.21037\/tlcr-24-127","article-title":"Biological characteristics and clinical treatment of pulmonary sarcomatoid carcinoma: A narrative review","volume":"13","author":"Wei","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.ccell.2021.07.007","article-title":"The CD155\/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer","volume":"39","author":"Lambert","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2012.10.008","article-title":"Clinical impact of Ki-67 labeling index in non-small cell lung cancer","volume":"79","author":"Jakobsen","year":"2013","journal-title":"Lung Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1038\/sj.bjc.6602233","article-title":"Ki-67 expression and patients survival in lung cancer: Systematic review of the literature with meta-analysis","volume":"91","author":"Martin","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/00000478-200309000-00003","article-title":"Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth, and tumor cell motility: A clinicopathologic and immunohistochemical study of 31 cases","volume":"27","author":"Pelosi","year":"2003","journal-title":"Am. J. Surg. Pathol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2240\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T09:36:06Z","timestamp":1792488966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":33,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18142240"],"URL":"https:\/\/doi.org\/10.3390\/cancers18142240","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]}}}